- Baseline characteristics of the study participants (N=191).
| Characteristics | On-site | TELE | P-value |
|---|---|---|---|
| Age (mean ± SD) | 49.6±16.5 | 48.4±18.1 | 0.615 |
| Gender (n, %) | |||
| Males | 50 (43.9%) | 30 (39%) | |
| Females | 64 (56.1%) | 47 (61%) | 0.551 |
| Comorbidity (n, %) | |||
| Diabetes | 34 (29.8%) | 30 (39%) | 0.213 |
| Hypertension | 46 (40.4%) | 31 (40.3%) | 1 |
| Hyperlipidemia | 18 (15.8%) | 16 (20.8%) | 0.442 |
| Ischemic heart disease | 4 (3.5%) | 4 (5.2%) | 0.716 |
| CKD- on dialysis | 13 (11.4%) | 13 (16.9%) | 0.290 |
| Heart failure | 2 (1.8%) | 5 (6.5%) | 0.120 |
| Other | 37 (32.5%) | 31 (40.3%) | 0.284 |
| None | 14 (12.3%) | 3 (3.9%) | 0.68 |
| Indication for anticoagulation (n,%) | |||
| DVT | 29 (25.4%) | 29 (37.7%) | 0.079 |
| PE | 22 (19.3%) | 15 (19.5%) | 1 |
| AF | 18 (15.8%) | 11 (14.3%) | 0.839 |
| Stroke | 17 (14.9%) | 9 (11.7%) | 0.668 |
| Others | 42 (36.8%) | 27 (35.1%) | 0.878 |
| Intended duration of anticoagulation (n, %) | |||
| 3 months | 17 (15.2%) | 13 (16.9%) | |
| 6 months | 12 (10.7%) | 8 (10.4%) | 0.792 |
| 12 months | 0 (0%) | 1 (1.3%) | |
| Lifelong | 83 (74.1%) | 55 (71.4%) | |
| Target INR (n, %) | |||
| 2.0-3.0 | 108 (94.7%) | 73 (94.8%) | |
| 2.5-3.5 | 6 (5.3%) | 2 (2.6%) | 0.159 |
| Others | 0 (0%) | 2 (2.6%) | |
| Use of anti-thrombotic (n, %) | |||
| Aspirin | 23 (20.2%) | 12 (15.6%) | 0.452 |
| Clopidogrel | 5 (4.4%) | 5 (6.5%) | 0.528 |
| Use of NSAIDS (n, %) | 7 (6.1%) | 3 (3.9%) | 0.535 |
| Ibuprofen | 3 (2.6%) | 0 (0%) | 0.274 |
| Lornoxicam | 5 (4.4%) | 2 (2.6%) | 0.703 |
| Celecoxib | 0 (0%) | 1 (1.3%) | 0.403 |
TELE: telepharmacy, CKD: chronic kidney disease, DVT: deep vein thrombosis, PE: pulmonary embolism, MI: myocardial infarction, AF: atrial fibrillation, INR: International Normalized ratio, NSAIDS: non-steroidal anti-inflammatory drugs.